A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
The first global pivotal trial will be in first-line triple-negative breast cancer.
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
TLX101 follows Ipax-1 with an apparent success in an academic trial.
The company scraps nemvaleukin after the latest failure, of Artistry-6.
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
